Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome.

la Marca A, Egbe TO, Morgante G, Paglia T, Cianci A, De Leo V.

Hum Reprod. 2000 Jan;15(1):21-3. Erratum in: Hum Reprod 2000 Mar;15(3):736. Ciani A [corrected to Cianci A].

PMID:
10611182
3.

Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin.

Koivunen RM, Morin-Papunen LC, Ruokonen A, Tapanainen JS, Martikainen HK.

Hum Reprod. 2001 Dec;16(12):2546-51.

PMID:
11726572
4.

The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.

Unlühizarci K, Keleştimur F, Bayram F, Sahin Y, Tutuş A.

Clin Endocrinol (Oxf). 1999 Aug;51(2):231-6.

PMID:
10468995
5.
6.

The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.

Romualdi D, De Cicco S, Tagliaferri V, Proto C, Lanzone A, Guido M.

J Clin Endocrinol Metab. 2011 May;96(5):E821-4. doi: 10.1210/jc.2010-1725. Epub 2011 Feb 9.

PMID:
21307134
7.

Ovarian responses to hCG stimulation: insulin resistance/hyperinsulinaemia vs. insulin deficiency.

Witchel SF, Arslanian S.

Clin Endocrinol (Oxf). 1999 Jul;51(1):127-30.

PMID:
10468975
10.

[Effect of long-term treatment with metformin on steroid levels and parameters of insulin resistance in women with polycystic ovary syndrome].

Vrbíková J, Hill M, Stárka L, Cibula D, Snajderová M, Sulcová J, Vondra K, Bendlová B.

Cas Lek Cesk. 2001 Nov 8;140(22):688-94. Czech.

PMID:
11789058
11.

Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome.

Nascimento AD, Silva Lara LA, Japur de Sá Rosa-e-Silva AC, Ferriani RA, Reis RM.

Gynecol Endocrinol. 2013 Mar;29(3):246-9. doi: 10.3109/09513590.2012.736563. Epub 2012 Nov 30.

PMID:
23194004
12.

Effects of metformin on inappropriate LH release in women with polycystic ovarian syndrome and insulin resistance.

Ulloa-Aguirre A, Portocarrero L, Zariñán T, Olivares A, Carranza-Lira S, Veldhuis JD, López-Alvarenga JC.

Reprod Biomed Online. 2006 Jun;12(6):669-83.

PMID:
16792841
13.
15.

Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy.

Berker B, Emral R, Demirel C, Corapcioglu D, Unlu C, Kose K.

Gynecol Endocrinol. 2004 Sep;19(3):125-33.

PMID:
15697073
17.

17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.

Pasquali R, Patton L, Pocognoli P, Cognigni GE, Gambineri A.

J Clin Endocrinol Metab. 2007 Nov;92(11):4208-17. Epub 2007 Sep 4.

PMID:
17785360
18.
19.

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK.

Fertil Steril. 1998 Apr;69(4):691-6.

PMID:
9548159
20.

Effects of caloric intake timing on insulin resistance and hyperandrogenism in lean women with polycystic ovary syndrome.

Jakubowicz D, Barnea M, Wainstein J, Froy O.

Clin Sci (Lond). 2013 Nov;125(9):423-32. doi: 10.1042/CS20130071.

PMID:
23688334

Supplemental Content

Support Center